Clinical Trial Update: CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating CHF5993 and CHF1535 metered-dose inhalers on lung hyperinflation and exercise endurance in COPD patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF1535
• CHF5993

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 4 | Status: COMPLETED